CAMBRIDGE, Massachusetts, August 21, 2026, 04:33 EDT — U.S. cash markets remained shut while Nasdaq continued to allow premarket trades.
- Moderna closed Thursday at $133.32, maintaining a gain of 110.5% from its August 14 finish.
- The increase for the week represented an approximate $27.9 billion addition, based on the latest share count.
- This represents 9.3 times a $3 billion projection for melanoma sales in 2035.
Moderna, Inc. NASDAQ:MRNA has increased its market value by roughly $28 billion in the past week. This surge suggests investors’ expectations extend beyond the potential of melanoma treatment.
The stock finished Thursday at $133.32, falling 23.55% following a 176.97% jump on Wednesday. It was last seen at $139.10 before the market opened on Friday. Despite the decline, Thursday’s closing price remained 110.5% above last Friday’s level of $63.32.
The adjustment in pricing
| Date | MRNA price | Move | Approx. value change |
|---|---|---|---|
| Aug. 14 close | $63.32 | Initial level | — |
| Aug. 19 close | $174.38 | One-day gain of 176.97% | +$44.5 billion |
| Aug. 20 close | $133.32 | One-day drop of 23.55% | -$16.4 billion |
| Weekly net | — | Overall increase of 110.5% | +$27.9 billion |
The catalyst held scientific significance. Moderna and Merck & Co., Inc. NYSE:MRK reported that their Phase 3 INTerpath-001 trial achieved its targets for both recurrence-free survival and distant-metastasis-free survival. The study involved 1,137 participants with fully resected stage IIB-IV melanoma. Researchers noted no new safety issues.
The companies did not disclose hazard ratios or survival curves. Complete efficacy results are still lacking. Moderna stated it plans to share the data and work with regulators, while it maintains follow-up for overall survival.
Chief Executive Stéphane Bancel described the outcome as “an extraordinary milestone for Moderna, for mRNA science and, most importantly, for patients with cancer.” The statement refers to the company’s initial successful Phase 3 trial of a personalized neoantigen therapy. It does not confirm readiness for commercial production. Moderna
How the market assigns value
| Measure | Value | Investor read-through |
|---|---|---|
| Weekly rise in market value | $27.9 billion | Roughly 9.3 times projected melanoma sales for 2035 |
| Forecast for annual melanoma sales in 2035 | Up to $3.0 billion | Excluding the Moderna-Merck 50/50 profit share |
| Moderna’s total market value | $53.23 billion | Over sevenfold June cash level |
| Cash and investments as of June | $6.9 billion | Lower than March’s $7.5 billion |
| Revenue for Q2 | $145 million | Compared to $782 million net loss |
Barclays analysts quoted by Reuters forecast annual melanoma sales could reach as much as $3 billion by 2035. Moderna and Merck share profits evenly. The $27.9 billion weekly gain, therefore, comes to 9.3 times that projected annual revenue, prior to accounting for time, expenses or Merck’s portion.
The valuation remains viable if intismeran achieves success in multiple tumor types. Moderna and Merck are conducting trials in lung, bladder and kidney cancers as well. At the January update, the companies had eight programs ongoing in Phase 2 or Phase 3 trials.
Current and upcoming evidence
| Study | Patients | Disclosure | What remains |
|---|---|---|---|
| Phase 3 INTerpath-001 | 1,137 | Endpoint goals for RFS and DMFS achieved | Details on hazard ratios, curve data, overall survival figures |
| Phase 2b KEYNOTE-942 | 157 | Recurrence-or-death risk reduced by 49% at five years | Further confirmation in Phase 3 specifics |
| Broader program | Eight trials | Coverage: melanoma, lung, bladder, kidney | Generalizability across tumor types |
The previous Phase 2b trial serves as a point of comparison. At five years, the combination therapy lowered the risk of recurrence or death by 49% compared to Keytruda by itself. Only 157 patients were part of that study. The larger Phase 3 results will show if this outcome is maintained in a larger group.
Analyst ratings
| Analyst / firm | Rating | Target | Date |
|---|---|---|---|
| Michael Yee / UBS | Hold | $150 | Aug. 20 |
| Alec Stranahan / BofA Securities | Hold, upgrade | $170 | Aug. 19 |
| Luca Issi / RBC Capital | Hold | $130 | Aug. 19 |
| Andrew Tsai / Jefferies | Hold | $60 | Aug. 19 |
| Jessica Fye / J.P. Morgan | Sell | $40 | Aug. 19 |
| 15-analyst consensus | 2 buy / 12 hold / 1 sell | Average $82.62 | Past 3 months |
The mean target is 38% lower than Thursday’s closing price. Analyst targets span from $40 to $170. This wide spread highlights how a single binary clinical outcome has surpassed traditional modeling approaches.
Moderna needs to continue financing its extensive pipeline. The company reported second-quarter revenue of $145 million and a net loss of $782 million. As of June 30, it had $6.9 billion in cash and investments, prior to a $950 million litigation payout in July.
Risks: full Phase 3 results might underwhelm, regulators could request extended monitoring, and custom manufacturing could limit profitability. Melanoma demand could also lag behind projections.
Looking ahead to next week, the main issue is clear. Investors require proof that the platform can support the $28 billion revaluation, rather than relying on a single positive trial outcome.
Related articles: NASDAQ:MRNA
